Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Lin Wu

34PUBLICATIONS
120CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markersEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

Sort by Publication Date:
|Mar 28, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Byoung Chul Cho, Rama Balaraman, Hua-Jun Chen

|Mar 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun

|Feb 02, 2026
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.

Fan Zhang, Zhendong Zheng, Hongmei Zhang

|Dec 07, 2025
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.

Yi-Long Wu, Lin Wu, Nan Bi

|Dec 01, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

Pascale Tomasini, Yongsheng Wang, Yongsheng Li

|Oct 02, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.

Jian Li, Ting Deng, Yanhong Gu

Pageof 6

Frequent Collaborators

6 joint publications

Ying Cheng

6 joint publications

Yi-Long Wu

3 joint publications

Qian Chu

3 joint publications

Jingyi Wang

2 joint publications

Tony Mok

2 joint publications

Shun Lu

2 joint publications

James Chih-Hsin Yang

2 joint publications

Mengzhao Wang

2 joint publications

Jie Wang

2 joint publications

Qiming Wang

Frequent Collaborators

6 joint publications

Ying Cheng

6 joint publications

Yi-Long Wu

3 joint publications

Qian Chu

3 joint publications

Jingyi Wang

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

8.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.5K
Identification of EGFR and RAS Inhibitors using <em>Caenorhabditis elegans</em>
08:12

Identification of EGFR and RAS Inhibitors using <em>Caenorhabditis elegans</em>

Published on : Oct 05, 2020

3.4K
See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

8.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.5K
Identification of EGFR and RAS Inhibitors using <em>Caenorhabditis elegans</em>
08:12

Identification of EGFR and RAS Inhibitors using <em>Caenorhabditis elegans</em>

Published on : Oct 05, 2020

3.4K
See more related videos